3Niewczas MA,Ficociello LH,Johnson AC,et al.Serum con-centrations of markers of TNF alpha and Fas-mediatedpathways and renal function in nonproteinuric patients withtype 1 diabetes[J].Clin J Am Soc Nephrol,2009,4(1):62-70.
4Anel Gomez-Garcia,Gloria Martinez Torres,Luz E Ortega-Pierres.Rosuvastatin and metformin decrease inflammationand oxidative stress in patients with hypertension and dys-lipidemia[J].Rev Esp Cardiol,2007,60(12):1242-1249.
5Ogawa S,Kobori H,Ohashi N,et al.AngiotensinⅡtype 1receptor blockers reduce urinary angiotensinogen excretionand the levels of urinary markers of oxidative stress and in-flammation in patients with type 2 diabetic nephropathy[J].Biomark Insights,2009,4:97-102.
6Li X,Zhang N,Li Y,et al.Effects of metformin and rosiglita-zone on peripheral insulin resistance and β-cell function inobesity:a double-blind,randomized,controlled study[J].IntMed Res,2011,39(2):358-365.
7Eriksson A,Attvall S,Bonnier M,et al.Short-term effects ofmetformin in type 2 diabetes[J].Diabetes Obes Metab,2007,9(3):330-336.
8Anfossi G,Russo I,Bonomo K,et al.The cardiovascular ef-fects of metformin:further reasons to consider an old drugas a cornerstone in the therapy of type 2 diabetes melli-tus[J].Curr Vasc Pharmacol,2010,8(3):327-337.
9Bailey CJ.Merformin:effects on micro and macrovascularcomplications in type 2 diabetes[J].Cardiovasc Drugs Ther,2008,22(3):215-224.
10Paulsen T.How much do you know about metformin?[J].Di-abetes Self Manag,2010,27(4):28-30.
